Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People with a confirmed diagnosis (from tissue testing) of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
• People whose cancer has shown signs of growing on scans while taking a PARP inhibitor drug, or after finishing it, and where that PARP inhibitor was the most recent cancer treatment received.
• People who took a PARP inhibitor for at least 6 months, either as a first treatment or for returning cancer.
• People with no more than 3 areas of cancer that are growing or progressing.
• People where each growing area of cancer is smaller than 4 cm across and is considered suitable for a type of targeted radiation treatment called SBRT, as assessed by the trial's specialist review team.
• People with cancer that can be measured on a CT or MRI scan using standard measurement criteria (people whose only sign of progression is a rising blood marker called CA125, without measurable disease on scans, would generally not be eligible — confirm with trial site).
• People for whom restarting a PARP inhibitor drug would not be medically unsafe.
• People for whom surgery to treat returning cancer is not planned.
• People whose general health and organ function are considered adequate to safely receive SBRT radiation treatment, as assessed by the treating doctor.
• People with a good general level of daily functioning (able to carry out normal daily activities, with at most mild limitations from their illness).
• People with a life expectancy of at least 6 months.
• Women who could potentially become pregnant must have a confirmed negative pregnancy test (urine or blood) within 72 hours before starting treatment. Women considered not at risk of pregnancy include those who are post-menopausal meeting specific hormonal criteria, those who have had certain permanent surgical procedures (such as hysterectomy or removal of both ovaries or both fallopian tubes — note: tubal ligation alone does not qualify), or those whose menopause was caused by radiation or chemotherapy and who have not had a period for more than 1 year.
• People willing to attend scheduled appointments, follow the treatment plan, and complete all required tests and trial procedures.
• People for whom a tissue sample (from diagnosis or a later biopsy) is available, or who are willing to have a biopsy to obtain one.
• People who are able to swallow and absorb oral (tablet) medication.
• People who are able to give written informed consent to participate.

Who may not be able to join:

• People with other medical conditions that would make receiving SBRT radiation treatment unsafe.
• People with brain metastases (cancer that has spread to the brain) that are currently growing or newly found, and cannot be treated with surgery or targeted brain radiation. Previously treated brain metastases that have been stable for 6 months or more may be acceptable (confirm with trial site).
• People who have previously received radiation treatment close to the areas now being considered for SBRT, if that prior treatment would make new SBRT unsafe.
• People who have taken part in another clinical trial involving an experimental treatment within the 4 weeks before joining this trial.
• Women who are pregnant or currently breastfeeding.
• Women of childbearing potential who are not willing to use a highly effective form of contraception.
• People who still have significant side effects from previous cancer treatments (above a mild level), except for certain exceptions such as Grade 2 hair loss or nerve-related side effects from chemotherapy (confirm with trial site).
• People who have had signs of a blocked bowel, or symptoms suggesting a partial bowel blockage, within the 6 weeks before joining the trial.
• People who have had another type of cancer that has been active or treated within the past 3 years, except for certain common skin cancers. Special confirmation steps and discussions with the trial team would be required in these cases (confirm with trial site).
• People who the treating doctor considers unsuitable for the trial or unlikely to follow the trial's requirements.

Important: Always verify eligibility with the trial site directly before applying.